ALPINE IMMUNE SCIENCES INC (ALPN) Stock Analyst Ratings
USA - NASDAQ:ALPN - US02083G1004 - Common Stock
64.97 USD
+0.01 (+0.02%)
64.99 USD
+0.02 (+0.03%)
ChartMill assigns a Buy % Consensus number of 76% to ALPN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 62.73. This target is -3.45% below the current price.
ALPN was analyzed by 15 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about ALPN.
In the last month the buy percentage fell by 11 points. So the trust of analysts is decreasing.
ALPN was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-05-16 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-04-16 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-04-12 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-04-11 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2024-04-11 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2024-04-11 | Wedbush | Downgrade | Outperform -> Neutral |
| 2024-04-11 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2024-04-09 | Guggenheim | Initiate | Buy |
| 2024-03-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-19 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-19 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-03-19 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-03-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-02-15 | Wolfe Research | Initiate | Outperform |
| 2024-01-26 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-12-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-15 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-11-03 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-11-03 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-11-03 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-10-18 | Berenberg | Initiate | Buy |
| 2023-10-05 | RBC Capital | Initiate | Outperform |
| 2023-09-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-09-01 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-08-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-15 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-08-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
ALPINE IMMUNE SCIENCES INC / ALPN FAQ
What is the price target for ALPN stock?
15 analysts have analysed ALPN and the average price target is 62.73 USD. This implies a price decrease of -3.45% is expected in the next year compared to the current price of 64.97.
What is the consensus rating for ALPINE IMMUNE SCIENCES INC (ALPN) stock?
The consensus rating for ALPINE IMMUNE SCIENCES INC (ALPN) is 76 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover ALPINE IMMUNE SCIENCES INC (ALPN) stock?
The number of analysts covering ALPINE IMMUNE SCIENCES INC (ALPN) is 15.